Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine for the treatment of sepsis
IRCT20100228003449N32Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Nov 2024
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in sepsis comparing Colchicine plus standard care with Placebo plus standard care (2 arms). Primary endpoint: Efficacy of colchicine on incidence of sepsis-induced organ failure. Started Nov 2024; status: completed.
02
Drugs
colchicine
03
Conditions
sepsis
Beyond the preview
Go deeper on IRCT20100228003449N32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20100228003449N32.